Abscopal responses in patients with metastatic melanoma involving skin and subcutaneous tissues treated with intralesional IL2 plus BCG
Cutaneous melanoma is relatively common with increasing incidence and significant mortality. While the mainstay of therapy is surgical, patients with stage III and IV disease fare poorer than those with early-stage disease and often benefit from adjuvant therapies. While systemic immunotherapy has c...
Main Authors: | Dejan Vidovic, Lucy Kathryn Helyer, Sylvia Pasternak, Carman Anthony Giacomantonio |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2023-04-01
|
Series: | Frontiers in Oncology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2023.1160269/full |
Similar Items
-
Insights into the Molecular Mechanisms Behind Intralesional Immunotherapies for Advanced Melanoma
by: Dejan Vidovic, et al.
Published: (2020-05-01) -
Cutaneous Breast Cancer Metastasis Is Effectively Treated With Intralesional Interleukin-2 and Imiquimod: A Case Report and Brief Literature Review
by: Ashley Drohan, et al.
Published: (2022-05-01) -
Resolution of Metastatic Subungal Eccrine Porocarcinoma Treated with Intralesional Interleukin-2
by: Ashley Drohan, et al.
Published: (2020-12-01) -
Intratumoral therapies and in-situ vaccination for melanoma
by: Laura A. Huppert, et al.
Published: (2022-05-01) -
Advances in Intralesional Therapy for Locoregionally Advanced and Metastatic Melanoma: Five Years of Progress
by: Danielle K. DePalo, et al.
Published: (2023-02-01)